Published in J Asthma on April 01, 2005
Asthma control in Canada remains suboptimal: the Reality of Asthma Control (TRAC) study. Can Respir J (2006) 3.27
Identification of asthmatic children using prescription data and diagnosis. Eur J Clin Pharmacol (2007) 1.43
Implementing practice guidelines: a workshop on guidelines dissemination and implementation with a focus on asthma and COPD. Can Respir J (2006) 1.32
Development and pilot testing of a mobile health solution for asthma self-management: asthma action plan smartphone application pilot study. Can Respir J (2013) 0.90
Spirometry in primary care: an analysis of spirometery test quality in a regional primary care asthma program. Can Respir J (2012) 0.88
Using a knowledge translation framework to implement asthma clinical practice guidelines in primary care. Int J Qual Health Care (2012) 0.88
Factors associated with poor asthma control in children aged five to 13 years. Can Respir J (2006) 0.84
The use of spirometry in a primary care setting. Int J Gen Med (2009) 0.76
Are peak flow meters readily available in community pharmacies? Can Pharm J (Ott) (2016) 0.75
Caregiver education to promote appropriate use of preventive asthma medications: what is happening in primary care? J Asthma (2015) 0.75
Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med (2012) 22.96
Contemporary management of chronic obstructive pulmonary disease: scientific review. JAMA (2003) 4.88
Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular diseases? The potential role of systemic inflammation in chronic obstructive pulmonary disease. Circulation (2003) 4.63
The relationship between reduced lung function and cardiovascular mortality: a population-based study and a systematic review of the literature. Chest (2005) 4.41
Small-airway obstruction and emphysema in chronic obstructive pulmonary disease. N Engl J Med (2011) 4.16
Effects of fluticasone on systemic markers of inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2004) 3.88
The effects of fluticasone with or without salmeterol on systemic biomarkers of inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2008) 3.85
Simvastatin for the prevention of exacerbations in moderate-to-severe COPD. N Engl J Med (2014) 3.51
The lung tissue microbiome in chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2012) 3.36
Mycobacterium avium complex pulmonary disease in patients without HIV infection. Chest (2004) 3.13
Prevalence of pulmonary embolism in acute exacerbations of COPD: a systematic review and metaanalysis. Chest (2008) 2.93
Club cell protein 16 and disease progression in chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2013) 2.82
COPD phenotypes in biomass smoke- versus tobacco smoke-exposed Mexican women. Eur Respir J (2013) 2.81
The relationship between lung inflammation and cardiovascular disease. Am J Respir Crit Care Med (2012) 2.54
Contemporary management of acute exacerbations of COPD: a systematic review and metaanalysis. Chest (2008) 2.41
Obesity is a risk factor for dyspnea but not for airflow obstruction. Arch Intern Med (2002) 2.36
Why do some countries publish more than others? An international comparison of research funding, English proficiency and publication output in highly ranked general medical journals. Eur J Epidemiol (2004) 2.34
The effects of inhaled corticosteroids in chronic obstructive pulmonary disease: a systematic review of randomized placebo-controlled trials. Am J Med (2002) 2.26
Vascular risk in chronic obstructive pulmonary disease: role of inflammation and other mediators. Can J Cardiol (2012) 2.22
Chronic obstructive pulmonary disease as a risk factor for cardiovascular morbidity and mortality. Proc Am Thorac Soc (2005) 2.17
The obesity paradox in patients with peripheral arterial disease. Chest (2008) 2.09
Lung eQTLs to help reveal the molecular underpinnings of asthma. PLoS Genet (2012) 2.09
Inhaled corticosteroids for chronic obstructive pulmonary disease. BMJ (2012) 2.04
The growing burden of chronic obstructive pulmonary disease and lung cancer in women: examining sex differences in cigarette smoke metabolism. Am J Respir Crit Care Med (2007) 2.04
Survival after lung volume reduction in chronic obstructive pulmonary disease: insights from small airway pathology. Am J Respir Crit Care Med (2007) 2.04
The interactions between cigarette smoking and reduced lung function on systemic inflammation. Chest (2005) 1.91
The impact of follow-up physician visits on emergency readmissions for patients with asthma and chronic obstructive pulmonary disease: a population-based study. Am J Med (2002) 1.90
Chronic obstructive pulmonary disease: a chronic systemic inflammatory disease. Respiration (2007) 1.88
Estimation of cancer mortality associated with repetitive computed tomography scanning. Am J Respir Crit Care Med (2005) 1.88
Pharmacological management to reduce exacerbations in adults with asthma: a systematic review and meta-analysis. JAMA (2004) 1.84
Late intervention with a myeloperoxidase inhibitor stops progression of experimental chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2012) 1.80
A pooled analysis of FEV1 decline in COPD patients randomized to inhaled corticosteroids or placebo. Chest (2007) 1.79
Connective tissue-activating peptide III: a novel blood biomarker for early lung cancer detection. J Clin Oncol (2009) 1.68
Low-dose inhaled corticosteroid therapy and risk of emergency department visits for asthma. Arch Intern Med (2002) 1.67
Everything prevents emphysema: are animal models of cigarette smoke-induced chronic obstructive pulmonary disease any use? Am J Respir Cell Mol Biol (2011) 1.67
Airway wall thickness assessed using computed tomography and optical coherence tomography. Am J Respir Crit Care Med (2008) 1.64
Arterial carbon dioxide tension on admission as a marker of in-hospital mortality in community-acquired pneumonia. Am J Med (2005) 1.64
An Official American Thoracic Society/European Respiratory Society Statement: Research questions in chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2015) 1.63
Lung disease due to the more common nontuberculous mycobacteria. Chest (2006) 1.62
Molecular signature of smoking in human lung tissues. Cancer Res (2012) 1.50
The complex relationship of serum adiponectin to COPD outcomes COPD and adiponectin. Chest (2012) 1.50
Statins reduce ambient particulate matter-induced lung inflammation by promoting the clearance of particulate matter, < 10 μm from lung tissues. Chest (2013) 1.46
Novel genes for airway wall thickness identified with combined genome-wide association and expression analyses. Am J Respir Crit Care Med (2015) 1.44
Tuberculosis in immigrants to Canada. A global problem which requires a global solution. Can J Public Health (2002) 1.44
Novel properties of statins: suppression of the systemic and bone marrow responses induced by exposure to ambient particulate matter (PM(10)) air pollution. Am J Physiol Lung Cell Mol Physiol (2012) 1.44
Female smokers beyond the perimenopausal period are at increased risk of chronic obstructive pulmonary disease: a systematic review and meta-analysis. Respir Res (2006) 1.44
Effect of the management of patients with chronic cough by pulmonologists and certified respiratory educators on quality of life: a randomized trial. Chest (2009) 1.43
Do chronic inhaled steroids alone or in combination with a bronchodilator prolong life in chronic obstructive pulmonary disease patients? Curr Opin Pulm Med (2007) 1.41
Integrative approach to quality assessment of medical journals using impact factor, eigenfactor, and article influence scores. PLoS One (2010) 1.39
Particulate matter exposure induces persistent lung inflammation and endothelial dysfunction. Am J Physiol Lung Cell Mol Physiol (2008) 1.38
The risk of osteoporosis in Caucasian men and women with obstructive airways disease. Am J Med (2003) 1.36
Implementing practice guidelines: a workshop on guidelines dissemination and implementation with a focus on asthma and COPD. Can Respir J (2006) 1.32
The airway epithelium: more than just a structural barrier. Ther Adv Respir Dis (2011) 1.30
Acute exacerbation of chronic obstructive pulmonary disease: influence of social factors in determining length of hospital stay and readmission rates. Can Respir J (2008) 1.28
Can universal access to health care eliminate health inequities between children of poor and nonpoor families?: A case study of childhood asthma in Alberta. Chest (2003) 1.23
Serum PARC/CCL-18 concentrations and health outcomes in chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2011) 1.23
New and current clinical imaging techniques to study chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2009) 1.23
Marijuana and chronic obstructive lung disease: a population-based study. CMAJ (2009) 1.19
Asthma and COPD among aboriginals in Alberta, Canada. Chest (2002) 1.17
The airway epithelium nucleotide-binding domain and leucine-rich repeat protein 3 inflammasome is activated by urban particulate matter. J Allergy Clin Immunol (2012) 1.17
Impact of cardioselective beta-blockers on mortality in patients with chronic obstructive pulmonary disease and atherosclerosis. Am J Respir Crit Care Med (2008) 1.16
The role of female hormones on lung function in chronic lung diseases. BMC Womens Health (2011) 1.16
Contemporary burden of illness of congestive heart failure in Canada. Can J Cardiol (2003) 1.16
Statin reverses smoke-induced pulmonary hypertension and prevents emphysema but not airway remodeling. Am J Respir Crit Care Med (2010) 1.16
The relationship between telomere length and mortality in chronic obstructive pulmonary disease (COPD). PLoS One (2012) 1.12
Steroids for treatment of COPD exacerbations: less is clearly more. JAMA (2013) 1.12
Incremental value of pulmonary function and sputum DNA image cytometry in lung cancer risk prediction. Cancer Prev Res (Phila) (2011) 1.10
Particulate matter induces translocation of IL-6 from the lung to the systemic circulation. Am J Respir Cell Mol Biol (2010) 1.10
Progression of airway dysplasia and C-reactive protein in smokers at high risk of lung cancer. Am J Respir Crit Care Med (2005) 1.09
Chronic obstructive pulmonary disease: a novel risk factor for cardiovascular disease. Can J Physiol Pharmacol (2005) 1.08
Systemic inflammation and mortality in chronic obstructive pulmonary disease. Can J Physiol Pharmacol (2007) 1.05
Divergence of mechanisms regulating respiratory burst in blood and sputum eosinophils and neutrophils from atopic subjects. J Immunol (2003) 1.05
Treatment of Mycobacterium avium-intracellulare complex lung disease with a macrolide, ethambutol, and clofazimine. Chest (2003) 1.04
Canadian Cohort Obstructive Lung Disease (CanCOLD): Fulfilling the need for longitudinal observational studies in COPD. COPD (2012) 1.04
Effects of inhaled corticosteroids on airway inflammation in chronic obstructive pulmonary disease: a systematic review and meta-analysis. Int J Chron Obstruct Pulmon Dis (2012) 1.03
Refining susceptibility loci of chronic obstructive pulmonary disease with lung eqtls. PLoS One (2013) 1.02
Effects of increased primary care access on process of care and health outcomes among patients with asthma who frequent emergency departments. Am J Med (2004) 1.01
The relationship between birth weight and childhood asthma: a population-based cohort study. Arch Pediatr Adolesc Med (2004) 1.01
Effects of inhaled corticosteroids on sputum cell counts in stable chronic obstructive pulmonary disease: a systematic review and a meta-analysis. BMC Pulm Med (2005) 1.01
Acute lung injury induces cardiovascular dysfunction: effects of IL-6 and budesonide/formoterol. Am J Respir Cell Mol Biol (2010) 1.01
Systematic review of blood biomarkers in cystic fibrosis pulmonary exacerbations. Chest (2013) 1.01
Interleukin-6: a red herring or a real catch in COPD? Chest (2008) 1.00
Pharmacotherapy in pulmonary arterial hypertension: a systematic review and meta-analysis. Respir Res (2010) 0.97